

## WEST Search History

[Hide Items](#) [Restore](#) [Clear](#) [Cancel](#)

DATE: Monday, January 22, 2007

Hide? Set Name Query

Hit Count

*DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR*

<input type="checkbox"/>	L45	L43 and PARP-1	5
<input type="checkbox"/>	L44	L43 and nucleolin	13
<input type="checkbox"/>	L43	L42 and (apoptotic)adj(bodies)	1352
<input type="checkbox"/>	L42	L(detection)adj(assays)	5896538
<input type="checkbox"/>	L41	(apoptosis)adj(detection)adj(assays)	34
<input type="checkbox"/>	L40	L38 and (nucleolin)adj(antibod?)	0
<input type="checkbox"/>	L39	L38 and (PARP-1)adj(antibod?)	0
<input type="checkbox"/>	L38	L37 and blood	28
<input type="checkbox"/>	L37	(apoptosis)adj(detection)adj(assays)	34
<input type="checkbox"/>	L36	(PARP)same(apoptotic)adj(bod?)	4
<input type="checkbox"/>	L35	(nucleolin)same(apoptotic)adj(bodies)	2
<input type="checkbox"/>	L34	(nucleolin)same(serum)same(plasma)same(blood)	10

*DB=EPAB; PLUR=YES; OP=OR*

<input type="checkbox"/>	L33	WO-9603655-A1.did.	1
--------------------------	-----	--------------------	---

*DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR*

<input type="checkbox"/>	L32	L29 and anti-PARP	0
<input type="checkbox"/>	L31	L29 and anti-nucleolin	0
<input type="checkbox"/>	L30	L29 and nucleolin	0
<input type="checkbox"/>	L29	(circulating)adj(apoptotic)adj(bodies)	12
<input type="checkbox"/>	L28	L27 and nucleolin	6
<input type="checkbox"/>	L27	(530/387.1).ccls.	2729
<input type="checkbox"/>	L26	L22 and anti-nucleolin	1
<input type="checkbox"/>	L25	L22 and anti-PARP	7
<input type="checkbox"/>	L24	L23 and apoptosis	16
<input type="checkbox"/>	L23	L22 and nucleolin	39
<input type="checkbox"/>	L22	(435/7.1).ccls.	12323
<input type="checkbox"/>	L21	(mi)adj(yingchang)	3
<input type="checkbox"/>	L20	(yingchang)adj(mi)	0
<input type="checkbox"/>	L19	(bates)adj(paula)adj(j)	9
<input type="checkbox"/>	L18	(detection)same(apoptosis)same(anti-nucleolin)	1
<input type="checkbox"/>	L17	L16 and (uncleaved)	9

<input type="checkbox"/>	L16	(detection)same(apoptosis)and anti-PARP	83
<input type="checkbox"/>	L15	(detection)same(apoptosis)same(PARP-1)	2
<input type="checkbox"/>	L14	(detection)same(apoptosis)same(nucleolin)	3
<input type="checkbox"/>	L13	L11 and anti-PARP	38
<input type="checkbox"/>	L12	L11 and (anti-nucleolin)	1
<input type="checkbox"/>	L11	L10 and apoptosis	1356
<input type="checkbox"/>	L10	(apoptotic)adj(bodies)	1464
<input type="checkbox"/>	L9	(nucleolin)same(antibod?)same(apoptosis)	5
		<i>DB=EPAB; PLUR=YES; OP=OR</i>	
<input type="checkbox"/>	L8	WO-200061597-A1.did.	0
		<i>DB=DWPI; PLUR=YES; OP=OR</i>	
<input type="checkbox"/>	L7	200061597	2
		<i>DB=USPT; PLUR=YES; OP=OR</i>	
<input type="checkbox"/>	L6	6339075.pn.	1
<input type="checkbox"/>	L5	6325785.pn.	1
<input type="checkbox"/>	L4	6291643.pn.	1
<input type="checkbox"/>	L3	6048703.pn.	1
<input type="checkbox"/>	L2	5932475.pn.	1
<input type="checkbox"/>	L1	5925334.pn.	1

END OF SEARCH HISTORY

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSSPTA1644PNH

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* \* \* \* \* Welcome to STN International \* \* \* \* \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 OCT 23 The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded  
NEWS 4 OCT 30 CHEMLIST enhanced with new search and display field  
NEWS 5 NOV 03 JAPIO enhanced with IPC 8 features and functionality  
NEWS 6 NOV 10 CA/CAplus F-Term thesaurus enhanced  
NEWS 7 NOV 10 STN Express with Discover! free maintenance release Version 8.01c now available  
NEWS 8 NOV 20 CAS Registry Number crossover limit increased to 300,000 in additional databases  
NEWS 9 NOV 20 CA/CAplus to MARPAT accession number crossover limit increased to 50,000  
NEWS 10 DEC 01 CAS REGISTRY updated with new ambiguity codes  
NEWS 11 DEC 11 CAS REGISTRY chemical nomenclature enhanced  
NEWS 12 DEC 14 WPIDS/WPINDEX/WPIX manual codes updated  
NEWS 13 DEC 14 GBFULL and FRFULL enhanced with IPC 8 features and functionality  
NEWS 14 DEC 18 CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role  
NEWS 15 DEC 18 CA/CAplus patent kind codes updated  
NEWS 16 DEC 18 MARPAT to CA/CAplus accession number crossover limit increased to 50,000  
NEWS 17 DEC 18 MEDLINE updated in preparation for 2007 reload  
NEWS 18 DEC 27 CA/CAplus enhanced with more pre-1907 records  
NEWS 19 JAN 08 CHEMLIST enhanced with New Zealand Inventory of Chemicals  
NEWS 20 JAN 16 CA/CAplus Company Name Thesaurus enhanced and reloaded  
NEWS 21 JAN 16 IPC version 2007.01 thesaurus available on STN  
NEWS 22 JAN 16 WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8  
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* \* \* \* \* STN Columbus \* \* \* \* \* \* \* \* \* \* \*

FILE 'HOME' ENTERED AT 12:50:25 ON 22 JAN 2007

=> file medline embase biosis scisearch caplus  
COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE ENTRY	TOTAL SESSION
0.21	0.21

FILE 'MEDLINE' ENTERED AT 12:50:45 ON 22 JAN 2007

FILE 'EMBASE' ENTERED AT 12:50:45 ON 22 JAN 2007  
Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 12:50:45 ON 22 JAN 2007  
Copyright (c) 2007 The Thomson Corporation

FILE 'SCISEARCH' ENTERED AT 12:50:45 ON 22 JAN 2007  
Copyright (c) 2007 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 12:50:45 ON 22 JAN 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> s apoptotic bodies .  
L1 7817 APOPTOTIC BODIES

=> s l1 and blood  
L2 1025 L1 AND BLOOD

=> s 12 and plasma  
T3 120 L2 AND PLASMA

=> s 13 and serum  
1.4 34 1.3 AND SERUM

=> s 14 and detection

=> s 15 and nucleolin

=> d 16 cbib abs

=> d 16 cbib abs

L6 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN  
2004:20982 Document No. 140:90312 A method for the detection of apoptosis via determination of nucleolin and/or PARP-1 in the sample. Bates, Paula J.; Mi, Yingchang (University of Louisville Research Foundation, Inc., USA). PCT Int. Appl. WO 2004003554 A1 20040108, 66 pp.  
DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2.  
APPLICATION: WO 2003-US20167 20030626. PRIORITY: US 2002-392143P 20020626.

AB Methods for the detection of apoptosis by measuring apoptotic bodies shed by apoptotic cells are provided, as are kits to carry out such methods. The method comprises preparing a sample from which cells have been removed and determining at least one of nucleolin and PARP-1 in the sample. The detection of either (or both) compds. comprises the detection of a

nucleolin (PARP-1)-binding mol.-nucleolin (PARP-1) complex. The binding mols. are anti-nucleolin (anti-PARP-1) antibodies and for nucleolin also guanosine-rich oligonucleotides. The sample can be blood, serum, plasma, tissue, tissue culture medium, or sputum. The method can be used to determine excessive apoptosis via preparing a blood sample from a subject suspected of having a disease selected from the group consisting of AIDS, neurodegenerative disease, ischemic injury, autoimmune disease, tumor, cancer, viral infection, acute inflammation, and sepsis.

=> dup remove 15

PROCESSING COMPLETED FOR L5

L7 8 DUP REMOVE L5 (4 DUPLICATES REMOVED)

=> d 17 1-8 cbib abs

L7 ANSWER 1 OF 8 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

2006496393 EMBASE Circulating nucleic acids in plasma/serum and tumor progression: Are apoptotic bodies involved? An experimental study in a rat cancer model. Samos J.; Garcia-Olmo D.C.; Picazo M.G.; Rubio-Vitaller A.; Garcia-Olmo D.. Prof. D. Garcia-Olmo, Servicio de Cirugia General-C, Hospital Universitario La Paz, Paseo Castellana 261, 28046 Madrid, Spain. damian.garcia@uam.es. Annals of the New York Academy of Sciences Vol. 1075, pp. 165-173 2006. Editor: Swaminathan R.

Refs: 31.

ISSN: 0077-8923. E-ISSN: 1749-6632. ISBN: 157331627X. CODEN: ANYAA

Pub. Country: United States. Language: English. Summary Language: English. Entered STN: 20061027. Last Updated on STN: 20061027

AB The "genometastasis hypothesis" proposes that cell-free tumor nucleic acids might be able to transform host stem cells, and that this might be a pathway for the development of metastases. This theory is supported by previous experimental findings and is consistent with observations of other authors. It has been suggested that tumor DNA might be horizontally transferred by the uptake of apoptotic bodies and initiate the genetic changes that are necessary for tumor formation. In addition, apoptotic bodies have been proposed as possible vehicles that protect the nucleic acids circulating in the plasma from enzymatic degradation. In the present study, we analyzed the presence of apoptotic bodies in serum and its relationship with tumor progression in a heterotopic model of colon cancer in the rat. We injected DHD/K12-PROb cancer cells subcutaneously into BD-IX rats and divided the animals into three groups according to the time between the injection of tumor cells and euthanasia. A control group of healthy animals was included (n = 6). After euthanasia, macroscopic metastases were assessed and samples of blood were collected. To detect apoptotic bodies in the sera, each sample was mixed with FITC-conjugated annexin V antibody in combination with propidium iodide and then analyzed by flow cytometry. Detection of apoptotic bodies was only significantly increased in the sera of a few tumor-bearing animals in late stages of tumor development. Thus, such particles appear not to be the vehicle of the cell-free tumor nucleic acids that are detected at early stages of cancer. .COPYRGT. 2006 New York Academy of Sciences.

L7 ANSWER 2 OF 8 MEDLINE on STN

DUPLICATE 1.

2006670327. PubMed ID: 17108207. Circulating nucleic acids in plasma/serum and tumor progression: are apoptotic bodies involved? An experimental study in a rat cancer model. Samos Julia; Garcia-Olmo Dolores C; Picazo Maria G; Rubio-Vitaller Antonio; Garcia-Olmo Damian. (Experimental Research Unit, General University Hospital of Albacete, Albacete, Spain. ) Annals of the

New York Academy of Sciences, (2006 Sep) Vol. 1075, pp. 165-73. Journal code: 7506858. ISSN: 0077-8923. Pub. country: United States. Language: English.

AB The "genometastasis hypothesis" proposes that cell-free tumor nucleic acids might be able to transform host stem cells, and that this might be a pathway for the development of metastases. This theory is supported by previous experimental findings and is consistent with observations of other authors. It has been suggested that tumor DNA might be horizontally transferred by the uptake of apoptotic bodies and initiate the genetic changes that are necessary for tumor formation. In addition, apoptotic bodies have been proposed as possible vehicles that protect the nucleic acids circulating in the plasma from enzymatic degradation. In the present study, we analyzed the presence of apoptotic bodies in serum and its relationship with tumor progression in a heterotopic model of colon cancer in the rat. We injected DHD/K12-PROb cancer cells subcutaneously into BD-IX rats and divided the animals into three groups according to the time between the injection of tumor cells and euthanasia. A control group of healthy animals was included (n = 6). After euthanasia, macroscopic metastases were assessed and samples of blood were collected. To detect apoptotic bodies in the sera, each sample was mixed with FITC-conjugated annexin V antibody in combination with propidium iodide and then analyzed by flow cytometry. Detection of apoptotic bodies was only significantly increased in the sera of a few tumor-bearing animals in late stages of tumor development. Thus, such particles appear not to be the vehicle of the cell-free tumor nucleic acids that are detected at early stages of cancer.

L7 ANSWER 3 OF 8 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN 2006:279900 Document No.: PREV200600286904. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer. Kopreski, Michael S. [Inventor]. Portage, MI USA. ASSIGNEE: Oncomedx, Inc.. Patent Info.: US 06939671 20050906. Official Gazette of the United States Patent and Trademark Office Patents, (SEP 6 2005)

CODEN: OGUPE7. ISSN: 0098-1133. Language: English.

AB This invention relates to the use of tumor-derived or associated extracellular ribonucleic acid (RNA) found circulating in the plasma or serum fraction of blood for the detection, monitoring, or evaluation of cancer or premalignant conditions. Extracellular RNA may circulate as non-bound RNA, protein-bound RNA, lipid-RNA complexes, lipoprotein (proteolipid)-RNA complexes, protein-RNA complexes including within or in association with ribonucleoprotein complexes, nucleosomes, or within apoptotic bodies. Any intracellular RNA found in plasma or serum can additionally be detected by this invention. Specifically, this invention enables the extraction of circulating RNA from plasma or serum and utilizes nucleic acid amplification assays for the identification, detection, inference, monitoring, or evaluation of any neoplasm, benign, premalignant, or malignant, in humans or other animals, which might be associated with that RNA. Further, this invention allows the qualitative or quantitative detection of tumor-derived or associated extracellular RNA circulating in the plasma or serum of humans or animals with or without any prior knowledge of the presence of cancer or premalignant tissue.

L7 ANSWER 4 OF 8 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN 2006:243150 Document No.: PREV200600252319. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer. Kopreski, Michael S. [Inventor]. Long Valley, NJ USA. ASSIGNEE: OncoMEDx, Inc.. Patent Info.: US 06916634 20050712. Official Gazette of the United States Patent and Trademark Office Patents, (JUL 12 2005)

AB CODEN: OGUPE7. ISSN: 0098-1133. Language: English.  
This invention relates to the use of tumor-derived or associated extracellular ribonucleic acid (RNA) found circulating in the plasma or serum fraction of blood for the detection, monitoring, or evaluation of cancer or premalignant conditions. Extracellular RNA may circulate as non-bound RNA, protein-bound RNA, lipid-RNA complexes, lipoprotein (proteolipid)-RNA complexes, protein-RNA complexes including within or in association with ribonucleoprotein complexes, nucleosomes, or within apoptotic bodies. Any intracellular RNA found in plasma or serum can additionally be detected by this invention. Specifically, this invention enables the extraction of circulating RNA from plasma or serum and utilizes nucleic acid amplification assays for the identification, detection, inference, monitoring, or evaluation of any neoplasm, benign, premalignant, or malignant, in humans or other animals, which might be associated with that RNA. Further, this invention allows the qualitative or quantitative detection of tumor-derived or associated extracellular RNA circulating in the plasma or serum of humans or animals with or without any prior knowledge of the presence of cancer or premalignant tissue.

L7 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN  
2004:20982 Document No. 140:90312 A method for the detection of apoptosis via determination of nucleolin and/or PARP-1 in the sample. Bates, Paula J.; Mi, Yingchang (University of Louisville Research Foundation, Inc., USA). PCT Int. Appl. WO 2004003554 A1 20040108, 66 pp.  
DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2.  
APPLICATION: WO 2003-US20167 20030626. PRIORITY: US 2002-392143P  
20020626.

AB Methods for the detection of apoptosis by measuring apoptotic bodies shed by apoptotic cells are provided, as are kits to carry out such methods. The method comprises preparing a sample from which cells have been removed and determining at least one of nucleolin and PARP-1 in the sample. The detection of either (or both) compds. comprises the detection of a nucleolin (PARP-1)-binding mol.-nucleolin (PARP-1) complex. The binding mols. are anti-nucleolin (anti-PARP-1) antibodies and for nucleolin also guanosine-rich oligonucleotides. The sample can be blood, serum, plasma, tissue, tissue culture medium, or sputum. The method can be used to determine excessive apoptosis via preparing a blood sample from a subject suspected of having a disease selected from the group consisting of AIDS, neurodegenerative disease, ischemic injury, autoimmune disease, tumor, cancer, viral infection, acute inflammation, and sepsis.

L7 ANSWER 6 OF 8 MEDLINE on STN DUPLICATE 2  
2004090891. PubMed ID: 14718398. Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics. El-Hefnawy Talal; Raja Siva; Kelly Lori; Bigbee William L; Kirkwood John M; Luketich James D; Godfrey Tony E. (Division of Thoracic Surgery, School of Medicine, Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA 15213, USA.) Clinical chemistry, (2004 Mar) Vol. 50, No. 3, pp. 564-73. Electronic Publication: 2004-01-12. Journal code: 9421549. ISSN: 0009-9147. Pub. country: United States. Language: English.

AB BACKGROUND: Several recent reports have described the detection of circulating, cancer-related RNA molecules in serum or

plasma from cancer patients, but little is known about the biology of this extracellular RNA. We aimed to determine how RNA is protected against degradation in serum, to optimize RNA isolation from large volumes of serum, and to test our optimized assays for serum-based cancer detection. METHODS: We used quantitative reverse transcription-PCR (QRT-PCR) analysis to investigate the isolation and biology of extracellular plasma RNA. We then examined the presence of amplifiable RNA transcripts in plasma and serum from controls and from patients with esophageal cancer and malignant melanoma. RESULTS: We found that extracellular RNA in plasma is highly degraded and can be isolated most efficiently by guanidinium-phenol extraction followed by precipitation. Extracellular RNA is stable in serum for up to 3 h but is destroyed immediately by addition of detergents. Extracellular RNA can be captured on 0.2 microm filters, allowing concentration of RNA from several milliliters of plasma. When we concentrated RNA from up to 4 mL of serum, detection of cancer-related transcripts in serum from cancer patients and controls was infrequent and inconsistent. CONCLUSIONS: Extracellular RNA is most likely protected within protein or lipid vesicles, possibly apoptotic bodies, which can be disrupted by detergents. Despite optimizing many aspects of plasma RNA detection, we were unable to reproducibly detect cancer-related transcripts. Our data suggest that measurement of circulating RNA may not be a good approach to early cancer diagnosis.

L7 ANSWER 7 OF 8 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN 2002:113843 Document No.: PREV200200113843. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer. Kopreski, Michael S. [Inventor, Reprint author]. Long Valley, NJ, USA. ASSIGNEE: OncoMEDx, Inc., Long Valley, NJ, USA. Patent Info.: US 6329179 20011211. Official Gazette of the United States Patent and Trademark Office Patents, (Dec. 11, 2001) Vol. 1253, No. 2. <http://www.uspto.gov/web/menu/patdata.html>. e-file. CODEN: OGUPE7. ISSN: 0098-1133. Language: English.

AB This invention relates to the use of tumor-derived or associated extracellular ribonucleic acid (RNA) found circulating in the plasma or serum fraction of blood for the detection, monitoring, or evaluation of cancer or premalignant conditions. Extracellular RNA may circulate as non-bound RNA, protein-bound RNA, lipid-RNA complexes, lipoprotein (proteolipid)--RNA complexes, protein-RNA complexes including within or in association with ribonucleoprotein complexes, nucleosomes, or within apoptotic bodies. Any intracellular RNA found in plasma or serum can additionally be detected by this invention. Specifically, this invention enables the extraction of circulating RNA from plasma or serum and utilizes nucleic acid amplification assays for the identification, detection, inference, monitoring, or evaluation of any neoplasm, benign, premalignant, or malignant, in humans or other animals, which might be associated with that RNA. Further, this invention allows the qualitative or quantitative detection of tumor-derived or associated extracellular RNA circulating in the plasma or serum of humans or animals with or without any prior knowledge of the presence of cancer or premalignant tissue.

L7 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN 1997:650277 Document No. 127:315563 Extraction, amplification, and detection of extracellular tumor-derived RNA from plasma or serum to detect, monitor or evaluate cancer. Kopreski, Michael S. (Kopreski, Michael S., USA). PCT Int. Appl. WO 9735589 A1 19971002, 54 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG,

US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1997-US3479 19970314. PRIORITY: US 1996-14730 19960326.

AB This invention relates to the use of tumor-derived or associated extracellular RNA found circulating in the plasma or serum fraction of blood for the detection, monitoring, or evaluation of cancer or premalignant conditions. Extracellular RNA may circulate as non-bound RNA, protein-bound RNA, lipid-RNA complexes, lipoprotein (proteolipid)-RNA complexes, protein-RNA complexes including within or in association with ribonucleoprotein complexes, nucleosomes, or within apoptotic bodies. Any intracellular RNA found in plasma or serum can addnl. be detected by this invention. Specifically, this invention enables the extraction of circulating RNA from plasma or serum and utilizes nucleic acid amplification assays for the identification, detection, inference, monitoring, or evaluation of any neoplasm, benign, premalignant, or malignant, in humans or other animals, which might be associated with that RNA. Further, this invention allows the qual. or quant. detection of tumor-derived or associated extracellular RNA circulating in the plasma or serum of humans or animals with or without any prior knowledge of the presence of cancer or premalignant tissue. In a typical example, keratin 19 mRNA is extracted from blood serum using the silica extraction method, followed by RT-PCR amplification with ELISA detection; pos. testing for extracellular keratin 19 mRNA suggests an impending cancer recurrence in a woman who had been treated for breast cancer two years ago.

=> s 12 and nucleolin  
L8 2 L2 AND NUCLEOLIN

=> dup remove 18  
PROCESSING COMPLETED FOR L8  
L9 2 DUP REMOVE L8 (0 DUPLICATES REMOVED)

=> d 19 1-2 cbib abs

L9 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN  
2004:20982 Document No. 140:90312 A method for the detection of apoptosis via determination of nucleolin and/or PARP-1 in the sample. Bates, Paula J.; Mi, Yingchang (University of Louisville Research Foundation, Inc., USA). PCT Int. Appl. WO 2004003554 A1 20040108, 66 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2003-US20167 20030626. PRIORITY: US 2002-392143P 20020626.

AB Methods for the detection of apoptosis by measuring apoptotic bodies shed by apoptotic cells are provided, as are kits to carry out such methods. The method comprises preparing a sample from which cells have been removed and determining at least one of nucleolin and PARP-1 in the sample. The detection of either (or both) compds. comprises the detection of a nucleolin (PARP-1)-binding mol.-nucleolin (PARP-1) complex. The binding mols. are anti-nucleolin (anti-PARP-1) antibodies and for nucleolin also guanosine-rich oligonucleotides. The sample can be blood, serum, plasma, tissue, tissue culture medium, or sputum. The method can be used to determine excessive apoptosis via preparing a blood sample from a subject suspected of having a disease selected from the group consisting of AIDS,

neurodegenerative disease, ischemic injury, autoimmune disease, tumor, cancer, viral infection, acute inflammation, and sepsis.

L9 ANSWER 2 OF 2 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN  
2003:201624 Document No.: PREV200300201624. Apoptosis in leukemia cells is  
accompanied by alterations in the levels and localization of  
nucleolin. Mi, Yingchang; Thomas, Shelia D.; Xu, Xiaohua; Casson,  
Lavona K.; Miller, Donald M.; Bates, Paula J. [Reprint Author]. 570 S.  
Preston St., 204B Baxter Bldg., Louisville, KY, 40202, USA.  
paula.bates@louisville.edu. Journal of Biological Chemistry, (March 7  
2003) Vol. 278, No. 10, pp. 8572-8579. print.  
CODEN: JBCHA3. ISSN: 0021-9258. Language: English.

AB Molecular defects in apoptotic pathways are thought to often contribute to the abnormal expansion of malignant cells and their resistance to chemotherapy. Therefore, a comprehensive knowledge of the mechanisms controlling induction of apoptosis and subsequent cellular disintegration could result in improved methods for prognosis and treatment of cancer. In this study, we have examined apoptosis-induced alterations in two proteins, nucleolin and poly(ADP-ribose) polymerase-1 (PARP-1), in U937 leukemia cells. Nucleolin is expressed at high levels in malignant cells, and it is a multifunctional and mobile protein that can shuttle among the nucleolus, nucleoplasm, cytoplasm, and plasma membrane. Here, we report our findings that UV irradiation or camptothecin treatment of U937 cells induced apoptosis and caused a significant change in the levels and localization of nucleolin within the nucleus. Additionally, nucleolin levels were dramatically decreased in extracts containing the cytoplasm and plasma membrane. These alterations could be abrogated by pre-incubation with an inhibitor of PARP-1 (3-aminobenzamide), and our data support a potential role for nucleolin in removing cleaved PARP-1 from dying cells. Furthermore, both nucleolin and cleaved PARP-1 were detected in the culture medium of cells undergoing apoptosis, associated with particles of a size consistent with apoptotic bodies. These results indicate that nucleolin plays an important role in apoptosis, and could be a useful marker for assessing apoptosis or detecting apoptotic bodies. In addition, the data provide a possible explanation for the appearance of nucleolin and PARP-1 autoantibodies in some autoimmune diseases.

=> s 12 and PARP-1  
L10 2 L2 AND PARP-1

=> dup remove 110  
PROCESSING COMPLETED FOR L10  
L11 2 DUP REMOVE L10 (0 DUPLICATES REMOVED)

=> d 111 1-2 cbib abs

L11 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN  
2004:20982 Document No. 140:90312 A method for the detection of apoptosis  
via determination of nucleolin and/or PARP-1 in the  
sample. Bates, Paula J.; Mi, Yingchang (University of Louisville Research  
Foundation, Inc., USA). PCT Int. Appl. WO 2004003554 A1 20040108, 66 pp.  
DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ,  
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE,  
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,  
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO,  
RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN,  
YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ,  
CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC,  
ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2.  
APPLICATION: WO 2003-US20167 20030626. PRIORITY: US 2002-392143P  
20020626.

AB Methods for the detection of apoptosis by measuring apoptotic

bodies shed by apoptotic cells are provided, as are kits to carry out such methods. The method comprises preparing a sample from which cells have been removed and determining at least one of nucleolin and PARP-1 in the sample. The detection of either (or both) compds.

comprises the detection of a nucleolin (PARP-1)-binding mol.-nucleolin (PARP-1) complex. The binding mols. are anti-nucleolin (anti-PARP-1) antibodies and for nucleolin also guanosine-rich oligonucleotides. The sample can be blood, serum, plasma, tissue, tissue culture medium, or sputum. The method can be used to determine excessive apoptosis via preparing a blood sample from a subject suspected of having a disease selected from the group consisting of AIDS, neurodegenerative disease, ischemic injury, autoimmune disease, tumor, cancer, viral infection, acute inflammation, and sepsis.

L11 ANSWER 2 OF 2 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN 2003:201624 Document No.: PREV200300201624. Apoptosis in leukemia cells is accompanied by alterations in the levels and localization of nucleolin. Mi, Yingchang; Thomas, Shelia D.; Xu, Xiaohua; Casson, Lavona K.; Miller, Donald M.; Bates, Paula J. [Reprint Author]. 570 S. Preston St., 204B Baxter Bldg., Louisville, KY, 40202, USA. paula.bates@louisville.edu. Journal of Biological Chemistry, (March 7 2003) Vol. 278, No. 10, pp. 8572-8579. print.

CODEN: JBCHA3. ISSN: 0021-9258. Language: English.

AB Molecular defects in apoptotic pathways are thought to often contribute to the abnormal expansion of malignant cells and their resistance to chemotherapy. Therefore, a comprehensive knowledge of the mechanisms controlling induction of apoptosis and subsequent cellular disintegration could result in improved methods for prognosis and treatment of cancer. In this study, we have examined apoptosis-induced alterations in two proteins, nucleolin and poly(ADP-ribose) polymerase-1 (PARP-1), in U937 leukemia cells. Nucleolin is expressed at high levels in malignant cells, and it is a multifunctional and mobile protein that can shuttle among the nucleolus, nucleoplasm, cytoplasm, and plasma membrane. Here, we report our findings that UV irradiation or camptothecin treatment of U937 cells induced apoptosis and caused a significant change in the levels and localization of nucleolin within the nucleus. Additionally, nucleolin levels were dramatically decreased in extracts containing the cytoplasm and plasma membrane. These alterations could be abrogated by pre-incubation with an inhibitor of PARP-1 (3-aminobenzamide), and our data support a potential role for nucleolin in removing cleaved PARP-1 from dying cells. Furthermore, both nucleolin and cleaved PARP-1 were detected in the culture medium of cells undergoing apoptosis, associated with particles of a size consistent with apoptotic bodies. These results indicate that nucleolin plays an important role in apoptosis, and could be a useful marker for assessing apoptosis or detecting apoptotic bodies. In addition, the data provide a possible explanation for the appearance of nucleolin and PARP-1 autoantibodies in some autoimmune diseases.

=> s 13 and poly-ADP-ribose polymerase 1  
L12 2 L3 AND POLY-ADP-RIBOSE POLYMERASE 1

=> dup remove 112  
PROCESSING COMPLETED FOR L12  
L13 2 DUP REMOVE L12 (0 DUPLICATES REMOVED)

=> d 113 1-2 cbib abs

L13 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN 2004:20982 Document No. 140:90312 A method for the detection of apoptosis via determination of nucleolin and/or PARP-1 in the sample. Bates, Paula J.; Mi, Yingchang (University of Louisville Research Foundation, Inc.,

USA). PCT Int. Appl. WO 2004003554 A1 20040108, 66 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2003-US20167 20030626. PRIORITY: US 2002-392143P 20020626.

AB Methods for the detection of apoptosis by measuring apoptotic bodies shed by apoptotic cells are provided, as are kits to carry out such methods. The method comprises preparing a sample from which cells have been removed and determining at least one of nucleolin and PARP-1 in the sample. The detection of either (or both) compds. comprises the detection of a nucleolin (PARP-1)-binding mol.-nucleolin (PARP-1) complex. The binding mols. are anti-nucleolin (anti-PARP-1) antibodies and for nucleolin also guanosine-rich oligonucleotides. The sample can be blood, serum, plasma, tissue, tissue culture medium, or sputum. The method can be used to determine excessive apoptosis via preparing a blood sample from a subject suspected of having a disease selected from the group consisting of AIDS, neurodegenerative disease, ischemic injury, autoimmune disease, tumor, cancer, viral infection, acute inflammation, and sepsis.

L13 ANSWER 2 OF 2 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN 2003:201624 Document No.: PREV200300201624. Apoptosis in leukemia cells is accompanied by alterations in the levels and localization of nucleolin. Mi, Yingchang; Thomas, Shelia D.; Xu, Xiaohua; Casson, Lavona K.; Miller, Donald M.; Bates, Paula J. [Reprint Author]. 570 S. Preston St., 204B Baxter Bldg., Louisville, KY, 40202, USA. paula.bates@louisville.edu. Journal of Biological Chemistry, (March 7 2003) Vol. 278, No. 10, pp. 8572-8579. print.

CODEN: JBCHA3. ISSN: 0021-9258. Language: English.

AB Molecular defects in apoptotic pathways are thought to often contribute to the abnormal expansion of malignant cells and their resistance to chemotherapy. Therefore, a comprehensive knowledge of the mechanisms controlling induction of apoptosis and subsequent cellular disintegration could result in improved methods for prognosis and treatment of cancer. In this study, we have examined apoptosis-induced alterations in two proteins, nucleolin and poly(ADP-ribose) polymerase-1 (PARP-1), in U937 leukemia cells. Nucleolin is expressed at high levels in malignant cells, and it is a multifunctional and mobile protein that can shuttle among the nucleolus, nucleoplasm, cytoplasm, and plasma membrane. Here, we report our findings that UV irradiation or camptothecin treatment of U937 cells induced apoptosis and caused a significant change in the levels and localization of nucleolin within the nucleus. Additionally, nucleolin levels were dramatically decreased in extracts containing the cytoplasm and plasma membrane. These alterations could be abrogated by pre-incubation with an inhibitor of PARP-1 (3-aminobenzamide), and our data support a potential role for nucleolin in removing cleaved PARP-1 from dying cells. Furthermore, both nucleolin and cleaved PARP-1 were detected in the culture medium of cells undergoing apoptosis, associated with particles of a size consistent with apoptotic bodies. These results indicate that nucleolin plays an important role in apoptosis, and could be a useful marker for assessing apoptosis or detecting apoptotic bodies. In addition, the data provide a possible explanation for the appearance of nucleolin and PARP-1 autoantibodies in some autoimmune diseases.

=> s apoptosis detection  
L14 1211 APOPTOSIS DETECTION

=> s 114 and antibod?  
L15 201 L14 AND ANTIBOD?

=> s 115 and nucleolin  
L16 1 L15 AND NUCLEOLIN

=> d 116 cbib abs

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN  
2004:20982 Document No. 140:90312 A method for the detection of apoptosis via determination of nucleolin and/or PARP-1 in the sample.

Bates, Paula J.; Mi, Yingchang (University of Louisville Research Foundation, Inc., USA). PCT Int. Appl. WO 2004003554 A1 20040108, 66 pp.  
DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2.

APPLICATION: WO 2003-US20167 20030626. PRIORITY: US 2002-392143P.  
20020626.

AB Methods for the detection of apoptosis by measuring apoptotic bodies shed by apoptotic cells are provided, as are kits to carry out such methods. The method comprises preparing a sample from which cells have been removed and determining at least one of nucleolin and PARP-1 in the sample. The detection of either (or both) compds. comprises the detection of a nucleolin (PARP-1)-binding mol.-nucleolin (PARP-1) complex. The binding mols. are anti-nucleolin (anti-PARP-1) antibodies and for nucleolin also guanosine-rich oligonucleotides. The sample can be blood, serum, plasma, tissue, tissue culture medium, or sputum. The method can be used to determine excessive apoptosis via preparing a blood sample from a subject suspected of having a disease selected from the group consisting of AIDS, neurodegenerative disease, ischemic injury, autoimmune disease, tumor, cancer, viral infection, acute inflammation, and sepsis.

=> s 115 and PARP-1  
L17 1 L15 AND PARP-1

=> d 117 cbib abs

L17 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN  
2004:20982 Document No. 140:90312 A method for the detection of apoptosis via determination of nucleolin and/or PARP-1 in the sample: Bates, Paula J.; Mi, Yingchang (University of Louisville Research Foundation, Inc., USA). PCT Int. Appl. WO 2004003554 A1 20040108, 66 pp.  
DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2.

APPLICATION: WO 2003-US20167 20030626. PRIORITY: US 2002-392143P.  
20020626.

AB Methods for the detection of apoptosis by measuring apoptotic bodies shed by apoptotic cells are provided, as are kits to carry out such methods. The method comprises preparing a sample from which cells have been removed and determining at least one of nucleolin and PARP-1 in the sample. The detection of either (or both) compds. comprises the detection

of a nucleolin (PARP-1)-binding mol.-nucleolin (PARP-1) complex. The binding mols. are anti-nucleolin (anti-PARP-1) antibodies and for nucleolin also guanosine-rich oligonucleotides. The sample can be blood, serum, plasma, tissue, tissue culture medium, or sputum. The method can be used to determine excessive apoptosis via preparing a blood sample from a subject suspected of having a disease selected from the group consisting of AIDS, neurodegenerative disease, ischemic injury, autoimmune disease, tumor, cancer, viral infection, acute inflammation, and sepsis.

=> s (bates p?/au or mi y?/au)  
L18           3149 (BATES P?/AU OR MI Y?/AU)

=> s l18 and apoptosis  
L19           41 L18 AND APOPTOSIS

=> s l19 and serum  
L20           7 L19 AND SERUM

=> dup remove 120  
PROCESSING COMPLETED FOR L20  
L21           3 DUP REMOVE L20 (4 DUPLICATES REMOVED)

=> d 121 1-3 cbib abs

L21 ANSWER 1 OF 3 SCISEARCH COPYRIGHT (c) 2007 The Thomson Corporation on STN  
2006:609547 The Genuine Article (R) Number: 055SJ. Proliferating effects of the flavonoids daidzein and quercetin on cultured chicken primordial germ cells through antioxidant action. Tang X Y; Zhang C Q (Reprint); Zeng W D; Mi Y L; Liu H Y. Zhejiang Univ, Dept Vet Med, Coll Anim Sci, 268 Kaixuan Rd, Hangzhou 310029, Zhejiang, Peoples R China (Reprint); Zhejiang Univ, Dept Vet Med, Coll Anim Sci, Hangzhou 310029, Zhejiang, Peoples R China. cqzhang@zju.edu.cn. CELL BIOLOGY INTERNATIONAL (MAY 2006) Vol. 30, No. 5, pp. 445-451. ISSN: 1065-6995. Publisher: ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD, 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND.  
Language: English.

\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

AB Primordial germ cells (PGCs) are undifferentiated pluripotent stem cells, whose proliferation is influenced by many internal and external factors. In the present study, a PGC-somatic cell co-culture model was established to evaluate effects of the flavonoids daidzein (DAI) and quercetin (QUE) on proliferation of PGCs from embryonic chickens. PGCs were isolated from the germinal ridge of 3.5-4 day embryos and cultured in 5% fetal calf serum (FCS)-supplemented Medium 199. PGC subculture was carried out on chicken embryonic fibroblast feeder (CEF) or follicular granulosa cell feeder (GCF) layers. The subcultured PGCs were challenged with flavonoids alone or in combination with a reactive oxygen substance (ROS)-producing system on CEF for 48 h. The results showed a better supporting effect of CEF than GCF. Flavonoids (1 μg/ml) significantly promoted PGC proliferation, which could be markedly inhibited by ROS. The oxidative damage by ROS was further manifest by decreased superoxide dismutase activity and glutathione levels. In addition, activation of protein kinase A (PKA) by forskolin significantly stimulated PGC proliferation, but PKA inhibitor H89 inhibited the proliferating effects induced by DAI and QUE. These results indicated that cultured PGCs respond to exogenous agents on proliferation and that antioxidant flavonoids could restore the intracellular antioxidant system and promote PGC proliferation via their antioxidant action involving the PKA signaling pathway. (c) 2006 International Federation for Cell Biology. Published by Elsevier Ltd. All rights reserved.

L21 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN  
2004:20982 Document No. 140:90312 A method for the detection of

apoptosis via determination of nucleolin and/or PARP-1 in the sample. Bates, Paula J.; Mi, Yingchang (University of Louisville Research Foundation, Inc., USA). PCT Int. Appl. WO 2004003554 A1 20040108, 66 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2003-US20167 20030626.

PRIORITY: US 2002-392143P 20020626.

AB Methods for the detection of apoptosis by measuring apoptotic bodies shed by apoptotic cells are provided, as are kits to carry out such methods. The method comprises preparing a sample from which cells have been removed and determining at least one of nucleolin and PARP-1 in the sample.

The detection of either (or both) compds. comprises the detection of a nucleolin (PARP-1)-binding mol.-nucleolin (PARP-1) complex. The binding mols. are anti-nucleolin (anti-PARP-1) antibodies and for nucleolin also guanosine-rich oligonucleotides. The sample can be blood, serum , plasma, tissue, tissue culture medium, or sputum. The method can be used to determine excessive apoptosis via preparing a blood sample from a subject suspected of having a disease selected from the group consisting of AIDS, neurodegenerative disease, ischemic injury, autoimmune disease, tumor, cancer, viral infection, acute inflammation, and sepsis.

L21 ANSWER 3 OF 3 MEDLINE on STN DUPLICATE 1  
2004456047. PubMed ID: 15364206. Effects of follicle-stimulating hormone and androgen on proliferation of cultured testicular germ cells of embryonic chickens. Mi Yuling; Zhang Caiqiao; Xie Meina; Zeng Weidong. (Department of Veterinary Medicine, College of Animal Sciences, Zhejiang University, Hangzhou 310029, China.) General and comparative endocrinology, (2004 Sep 15) Vol. 138, No. 3, pp. 237-46. Journal code: 0370735. ISSN: 0016-6480. Pub. country: United States. Language: English.

AB A germ-Sertoli cell coculture model was established to study effects of follicle-stimulating hormone (FSH) and testosterone (T) on testicular germ cell proliferation of the embryonic chickens. Germ and somatic cells were dispersed from 18-day-old embryonic testes and cultured in 96-well plates. Germ cells were characterized by expression of stem cell factor receptor c-kit. Germ cell proliferation was assessed by an increase in cell number and expression of proliferating cell nuclear antigen (PCNA). Results showed that the germ and Sertoli cells kept alive in serum-free McCoy's 5A medium supplemented with insulin, transferrin, and selenite (ITS medium). Germ cells adhered to the free surface of Sertoli cells that spread the filopodia and formed a monolayer in ITS medium. In the serum-containing medium, Sertoli cells displayed an increment with a flat squamous form and only a few very large germ cell masses were found in the free surface of Sertoli cells. Many germ cells showed apoptosis in the McCoy's 5A medium without ITS or serum. Only germ cells showed positive staining for c-kit in the coculture. Ovine FSH (0.25-1.0 IU/ml) significantly increased the number of germ cells, and PCNA-labeling index ( $P < 0.05$ ). FSH also induced stronger c-kit expression compared with the control. In the FSH-treated groups, germ cells were manifested distinct knob-like form. Similar stimulating effect was found in the germ cell number by T treatments ( $10(-7)$ - $10(-6)$ M). Furthermore, FSH (0.5 IU/ml) combined with T significantly promoted higher testicular germ cell proliferation ( $P < 0.05$ ) compared with either FSH or T alone, which indicated that interaction of FSH and T might be additive. The above results showed that the serum-free germ-Sertoli cell coculture model allowed evaluating hormonal regulation of testicular germ cell proliferation. FSH and T promoted testicular germ cell proliferation probably through indirect effects on Sertoli cells.

=> s 119 and plasma  
L22 6 L19 AND PLASMA

=> dup remove 122  
PROCESSING COMPLETED FOR L22  
L23 2 DUP REMOVE L22 (4 DUPLICATES REMOVED)

=> d 123 1-2 cbib abs

L23 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN  
2004:20982 Document No. 140:90312 A method for the detection of apoptosis via determination of nucleolin and/or PARP-1 in the sample. Bates, Paula J.; Mi, Yingchang (University of Louisville Research Foundation, Inc., USA). PCT Int. Appl. WO 2004003554 A1 20040108, 66 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2003-US20167 20030626.

PRIORITY: US 2002-392143P 20020626.

AB Methods for the detection of apoptosis by measuring apoptotic bodies shed by apoptotic cells are provided, as are kits to carry out such methods. The method comprises preparing a sample from which cells have been removed and determining at least one of nucleolin and PARP-1 in the sample.

The detection of either (or both) compds. comprises the detection of a nucleolin (PARP-1)-binding mol.-nucleolin (PARP-1) complex. The binding mols. are anti-nucleolin (anti-PARP-1) antibodies and for nucleolin also guanosine-rich oligonucleotides. The sample can be blood, serum, plasma, tissue, tissue culture medium, or sputum. The method can be used to determine excessive apoptosis via preparing a blood sample from a subject suspected of having a disease selected from the group consisting of AIDS, neurodegenerative disease, ischemic injury, autoimmune disease, tumor, cancer, viral infection, acute inflammation, and sepsis.

L23 ANSWER 2 OF 2 MEDLINE on STN DUPLICATE 1  
2003099862. PubMed ID: 12506112. Apoptosis in leukemia cells is accompanied by alterations in the levels and localization of nucleolin. Mi Yingchang; Thomas Shelia D; Xu Xiaohua; Casson Lavona K; Miller Donald M; Bates Paula J. (Molecular Targets Group, James Graham Brown Cancer Center, Department of Medicine, University of Louisville, Kentucky 40202, USA. ) The Journal of biological chemistry, (2003 Mar 7) Vol. 278, No. 10, pp. 8572-9. Electronic Publication: 2002-12-27. Journal code: 2985121R. ISSN: 0021-9258. Pub. country: United States. Language: English.

AB Molecular defects in apoptotic pathways are thought to often contribute to the abnormal expansion of malignant cells and their resistance to chemotherapy. Therefore, a comprehensive knowledge of the mechanisms controlling induction of apoptosis and subsequent cellular disintegration could result in improved methods for prognosis and treatment of cancer. In this study, we have examined apoptosis-induced alterations in two proteins, nucleolin and poly(ADP-ribose) polymerase-1 (PARP-1), in U937 leukemia cells. Nucleolin is expressed at high levels in malignant cells, and it is a multifunctional and mobile protein that can shuttle among the nucleolus, nucleoplasm, cytoplasm, and plasma membrane. Here, we report our findings that UV irradiation or camptothecin treatment of U937 cells induced apoptosis and caused a significant change in the levels and localization of nucleolin within the nucleus. Additionally, nucleolin levels were dramatically decreased in extracts containing the cytoplasm and plasma

membrane. These alterations could be abrogated by pre-incubation with an inhibitor of PARP-1 (3-aminobenzamide), and our data support a potential role for nucleolin in removing cleaved PARP-1 from dying cells. Furthermore, both nucleolin and cleaved PARP-1 were detected in the culture medium of cells undergoing apoptosis, associated with particles of a size consistent with apoptotic bodies. These results indicate that nucleolin plays an important role in apoptosis, and could be a useful marker for assessing apoptosis or detecting apoptotic bodies. In addition, the data provide a possible explanation for the appearance of nucleolin and PARP-1 autoantibodies in some autoimmune diseases.

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	117.45	117.66
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-7.80	-7.80

STN INTERNATIONAL LOGOFF AT 12:57:08 ON 22 JAN 2007